NutraIngredients-USA Global Round-up: CBD Down Under, silk peptides for memory, and more

By Stephen Daniells contact

- Last updated on GMT

© Getty Images / bluebay2014
© Getty Images / bluebay2014
It’s a global industry and there’s a lot happening. We know it’s not always easy keeping up with everything that’s happening around the world that could impact the US dietary supplements industry. The answer? Our weekly round-up of key news from across the globe.

CBD contributes to Bod Australia’s revenue growth

CBD-based products contributing significantly to Bod’s growth, with the Australian firm reporting a record US$872,240 (A$1.22m) revenue for Q4 2018. This included US$547,760 (A$766,000) in sales — a 260% increase from its Q1 results.

MediCabilis, a proprietary pharmaceutical-grade cannabis extract that is currently available in bottled oil format through the Special Access Scheme in Australia.

CEO Jo Patterson told NutraIngredients-Asia: “We’re doing lots of stuff in the cannabis and hemp space. We are developing a nutraceutical product that we will adapt to Australian market, so it will contain hemp seed oil, terpene and an herbal extract.

“We’ve also created another line for the OTC (over-the-counter) market through pharmacies. It contains CBD extract, terpene and an herbal extract, and will be sold in the UK and European markets.

“We’re really at the forefront of what’s going on from a prescription perspective, and we’re also at the forefront in terms of OTC opportunities.”

As there are regulatory restrictions on the use of CBD in Australia, Bod has taken to substituting CBD extract with hemp seed oil in the product formulations it sells in its home country.

For more on this story, please click HERE​.

Silk peptide supplements show cognitive health benefits

Brain health © Getty Images iLexx
© Getty Images / iLexx

Japan Central Pharma will launch a new supplement branded Memory Keep Ex formulated with silk peptides.

The product will be marketed towards parents, who would hopefully purchase the product for their children who are preparing for university entrance exams, Hisao Nakajima, the CEO of Japan Central Pharm (JCP) told our Asian edition​.

“The consumers usually buy our product 6 months before the university entrance exam,”​ said Nakajima.

According to the company, the mechanism of action involves promoting blood flow in the brain and activating the mitochondria of a brain cell. Clinical trials to study the effects of the product have reportedly been performed.

“High school students (in Japan) are studying very hard to enter a university, just like those in China and Korea. They try to pass the entrance examination and I will like to help them,”​ Nakajima explained when asked the reasons for targeting the high school students.

Nestlé’s new Irish R&D center

The food giant’s new global research center in Ireland will focus on developing innovations in milk-based maternal and infant nutrition products for the global market.

“Our Irish R&D Centre [sic] will benefit from Nestlé’s global R&D network and help to position Nestlé at the fore of infant and maternal nutritional product development, one of Nestlé’s most important growth drivers,”​ said Thomas Hauser, head of global product and technology development for Nestlé.

“With this new centre, we will increase the pace of our innovation capacity by enabling our scientists to explore innovative nutritional solutions for the crucial first 1,000 days of life.”

The R&D Centre is co-located with Nestlé’s Wyeth Nutrition manufacturing plant. Nestlé acquired Wyeth Nutrition’s Infant Formula business back in 2012.

“[The new R&D center] incorporates state-of-the-art laboratory facilities as well as a full pilot-scale manufacturing line to facilitate the development, and testing of new products from initial concept through to product deployment. The project investment was supported by Enterprise Ireland,” said Nestlé in a press release.

For more on this, please click HERE​.

Related topics: Markets

Related news

Show more

Follow us


View more